NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Transcripta Bio

Transcripta Bio

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://www.transcriptabio.com/

Last Round

Early Funding

Jul 22, 2026

Total Funding Raised

$26.71M

Company Overview

Transcripta Bio is a biotechnology company that utilizes AI and high-resolution transcriptomic data to accelerate drug discovery and therapeutic development.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

drug discoverytranscriptomicstherapeutic target identificationAI drug discoveryin silico drug discoveryvirtual screeningbiotech platformgene-disease mappingpredictive MLdrug repurposingdata as a serviceDaaStarget validationbiotech R&DAI-first biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Transcripta Bio Comparables

Compare Transcripta Bio with similar companies based on industry and business-model similarity.

Transcripta Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tahoe Therapeutics
87%
Arpeggio Biosciences
85%
Pepper Bio
84%

Transcripta Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingJul 22, 2026
VC RoundApr 29, 2024
Series ANov 5, 2021
GrantOct 1, 2021
SeedNov 23, 2020
Seed
Oct 12, 2020

Key People

Founding team and executive leadership

Christopher Moxham

Founder, Chief Executive Officer

Founding Team

Clayton Mellina

Chief Technology Officer

Executive Team

Transcripta Bio Investors

Notable investors and investment history

Transcripta Bio investors
InvestorRounds
Prototype CapitalSeed
BlueYard CapitalEarly Funding, Series A, VC Round, Seed
GaingelsVC Round
JAZZ Venture PartnersEarly Funding, Series A, VC Round, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 22, 2026

    $24M raised with participation from BlueYard Capital and Mayo Clinic.

  • May 30, 2025

    Collaborating with Microsoft Research on AI applications for medicine.

Transcripta Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Transcripta Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Transcripta Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range19
Year Founded2022
Last FundingJul 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.